FCM
PRAX icon

Frontier Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Frontier Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.8M Buy
74,207
+20,842
+39% +$6.6M 0.23% 163
2026
Q1 		$17.2M Buy
+53,365
New +$16.5M 0.18% 173

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Frontier Capital Management's PRAX Position: Q2 2026 in Review

Frontier Capital Management increased its Praxis Precision Medicines (PRAX) stake by 39% in Q2 2026, buying an estimated $6.6M and bringing the position to 74,207 shares worth $24.8M. The position accounts for 0.23% of the portfolio, ranked #163.

Frontier Capital Management first reported a position in PRAX in Q1 2026 and has held it in 2 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Frontier Capital Management held 74,207 shares of Praxis Precision Medicines worth $24.8M as of Q2 2026.
  • Frontier Capital Management bought 20,842 Praxis Precision Medicines shares in Q2 2026, an estimated $6.6M.
  • Praxis Precision Medicines made up 0.23% of Frontier Capital Management's portfolio in Q2 2026, its #163 holding.
  • Frontier Capital Management first reported a position in Praxis Precision Medicines in Q1 2026 and has held it in 2 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.